Jazz Pharmaceuticals plc — Director's Dealing 2010

Nov 19, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JAZZ PHARMACEUTICALS INC (JAZZ)
CIK: 0001232524
Period of Report: 2010-11-18

Reporting Person: Wissel Janne LT (SVP, Chief Regulatory Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-11-18	Common Stock	M	46663	$1.25	Acquired	152493	Direct
2010-11-18	Common Stock	S	46663	$15.05	Disposed	105830	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-11-18	Option (right to buy)	$1.25	M	46663	Disposed	2019-01-20	Common Stock (46663)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.35, inclusive.

F2: The reporting person undertakes to provide to Jazz Pharmaceuticals, Inc., any security holder of Jazz Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (1) to this Form 4.

F3: The options represented are vesting over three years measured from the vesting commencement date, January 21, 2009, with 1/3rd vesting on the first anniversary of the vesting commencment date and the remainder vesting in 24 equal monthly installments thereafter. On 11/18/2010, the Transaction Date, options representing 46,663 shares were excercisable.